ESTRO 2025 - Abstract Book

S1509

Clinical – Mixed sites & palliation

ESTRO 2025

Results: The median age of 11 patients enrolled was 60 years (IQR: 53-64)and most had a lung primary followed by breast. Median overall survival (OS) was 5.3 months (figure 2A) with a median follow up of 13.3 months.. There was a significant reduction in dyspnea symptoms post-RT (mean reduction: 2.0 (IQR: -3.0 to -2.0; p = 0.004), while pain response could not be assessed due to limited numbers. Significant reduction in target lesion volume was also noted (figure 2B). Only 1 patient experienced Grade 3 toxicity (necrosis; managed conservatively). Approximately 75% of patients survived beyond 3 months, which was the expected survival on BSC prior to SIB-Lattice RT.